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How ethical is your clinical trial?
As stakeholders in the ﬁeld of biomedical HIV
prevention research, we have seen how the
HIV⁄AIDS pandemic has greatly shaped what is
viewed as ethical conduct in research. To assess the
effectiveness of new HIV prevention technologies,
clinical trials must recruit large numbers of healthy,
HIV-negative individuals as study participants.
Research ethics stipulate that these new HIV preven-
tion strategies be tested for safety and effectiveness in
populations who need these interventions and are
likely to use them. Therefore, these trials are con-
ducted often as multi-site, international studies, and
with high-incidence populations who may be poor
or marginalised and consequently may have less
access to standard health care services. Frequently,
setting up a biomedical HIV prevention clinical trial
is a vast undertaking accompanied by the need for
investment in time, human resources and infrastruc-
ture. As a result of their size, these trials can have
impact on the surrounding community – a new
clinic may be built, jobs may be created and access
to better health interventions may become available.
The arrival of a large trial, however, if not conducted
in ways that are sensitive to the local environment
and locally determined priorities, may create conﬂict
or misunderstanding between researchers and the
community from which trial participants will be
recruited.
Through the activism in the 1980’s around AIDS
treatment trials, the biomedical ﬁeld saw, in many
ways for the ﬁrst time, how community stakeholders
not associated with the scientiﬁc ﬁeld could play a
role in setting the research agenda and making
important contributions to the clinical trials process
(3). Indeed, communities can play active roles in
determining research priorities, and providing
important input into trial implementation and moni-
toring (4). Recently, the need to rec-
ognise and standardise the
implementation of community par-
ticipation within the clinical trials
process was highlighted through
controversies that erupted between
researchers and local voices around
testing tenofovir disoproxil fumarate
(TDF) for the prevention of HIV
infection in pre-exposure prophy-
laxis (PrEP) studies in 2004 and
2005. In Cameroon, the Family
Health International PrEP trial was
halted by the Minister of Public Health, and in
Cambodia, the proposed PrEP trial funded by the
US National Institutes of Health and the Bill and
Melinda Gates Foundation was never implemented
by order of the Cambodian Prime Minister. In
Thailand, the US Centers for Disease Control and
Prevention PrEP study saw similar differences emerge
between community stakeholders and researchers,
although the trial was not stopped and is still
ongoing.
Analyses of these trials (5–8) indicate that poor
communication and a lack of mutual understanding
between trial communities and research teams pre-
vented the kinds of positive collaborations that
would have been required for such biomedical HIV
prevention trials to continue. In the above examples,
there was a considerable disconnect between the
intentions of researchers and what both local and
global community stakeholders felt was happening.
Review of these controversies shows clearly that
effective communication and building a valid negoti-
ation process are key elements of good community
engagement. Such breakdown in communication and
understanding which led to the loss of multiple
opportunities need not happen.
The PrEP trials in Cameroon, Thailand and Cam-
bodia are case studies of clinical trials reviewed and
approved by multiple ethics committees, yet subse-
quently found unacceptable by some community
stakeholders because of differing opinions of ethical
requirements for the conduct of research in their
communities. Lessons from these trials suggest it can
no longer be assumed that all proposed research that
requires broad recruitment from communities should
be implemented as determined by IRBs and research-
ers alone. Rather, communities, together with
researchers and IRBs, have an important role in
Is Institutional Review Board (IRB) approval and a rigorous
informed consent process enough? It is our view that this is
no longer the case. Conventional research ethics emphasise
the importance of weighing the risks and beneﬁts for
prospective participants as one of the key determinants of
deeming a clinical trial ethical. We support the notion that
ethical obligations of research should include considerations
not only at the individual level, but also at the community
level (1,2).
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Communities,
together with
researchers
and IRBs, have
an important
role in
determining
whether a
particular
study is
appropriate
for a particular
location and
timedetermining whether a particular study is appropriate
for a particular location and time.
Researchers conducting biomedical HIV preven-
tion research do have an ethical obligation to engage
communities. Guidance point two of the UN-
AIDS⁄WHO Ethical Considerations in Biomedical
HIV Prevention Trials (9) clearly states that research-
ers should consult with communities in a participa-
tory process to ensure ethical and scientiﬁc quality of
proposed research. The International Ethical Guide-
lines for Biomedical Research Involving Human Sub-
jects by the Council for International Organizations
of Medical Sciences (CIOMS) (10) state that research
should be responsive to the health needs of commu-
nities; consulting with communities on the research
process can help ensure that this ethical responsibil-
ity is met. Our belief is that these discussions can
and should happen early in the process, and in a
manner that respects local culture and local priori-
ties. Projects that are more likely to be successful are
those that allow researchers and community stake-
holders to come together to share ideas on research
priorities and how best to conduct trials. A commu-
nity that is respected and treated as a partner rather
than as a supplier of ‘research subjects’ is more likely
to be supportive of a proposed clinical trial.
Although the process of engaging with communities
can never guarantee collaboration free of controversy
or free of considerable differences of opinion (11),
productive dialogues with community stakeholders
can translate into beneﬁts for the research and for
communities. Discussions with community stake-
holders can help reﬁne study procedures to the local
context. This in turn may maximise results (12–15)
and lead to more effective recruitment and enrol-
ment strategies, better retention rates and stronger
adherence to the study product.
Community engagement is increasingly being
recognised as an essential component of ethical con-
duct of biomedical HIV prevention trials. Good Par-
ticipatory Practice Guidelines (GPP) in Biomedical
HIV Prevention Trials (16) is the ﬁrst set of global
guidelines to outline detailed steps to ensure com-
munity engagement within the context of biomedical
HIV prevention trials. The GPP guidelines are
designed for trial sponsors and implementers and
identify core principles for the foundation of relation-
ships between trial entities and community stake-
holders. Examples of such principles are respect,
research literacy, ethical and scientiﬁc integrity and
transparency. The minimum elements of good commu-
nity practice explain how speciﬁc activities and
actions can facilitate appropriate community engage-
ment at each stage of the trial life-cycle. The GPP
guidelines are broad enough to allow for variation in
trial sites across the globe, but speciﬁc enough to
provide a suitable framework to facilitate successful
adoption of key activities.
A unique aspect of the GPP guidelines is that they
can be utilised as a tool to assess effective collabora-
tive processes by community stakeholders, research-
ers and trials sponsors. With a potentially powerful
tool at the disposal of community stakeholders, it is
expected that monitoring of collaborative processes
within biomedical HIV prevention trials, as well as
other forms of research, will become more rigorous
in time.
Institutional Review Board approval of clinical tri-
als is an essential ethical component of the research
process. A thorough informed consent process is also
essential. However, ethics is a ﬁeld that evolves and
changes over time. In the ﬁeld of biomedical HIV
prevention trials, there has been a shift in the expec-
tations of stakeholders with respect to what is per-
ceived as ethical conduct of research. Support for
community engagement as an ethical component of
the research process can also be seen outside the ﬁeld
of biomedical HIV prevention research. Increasingly,
guidance documents (17,18) are recognising involve-
ment of community stakeholders as an ethical obli-
gation of researchers. At the same time, there are
examples of communities in various settings organis-
ing themselves to act as self-determining gatekeepers
of ethical research – choosing what research they are
willing to allow and support within their locales
(19,20).
Given these developments, we believe that
researchers should embrace this new direction as one
possible avenue to enhance the successes of their tri-
als and improve the ethical conduct of their research.
They will not be alone. There is existing evidence of
the importance and feasibility of such community
engagement in the broader health ﬁeld (21–25). In
recent years, funding opportunities for community
based and community based participatory research
have been added to the portfolios of, among others,
the US National Institutes of Health and the Cana-
dian Institutes of Health Research. These develop-
ments reinforce the need for institutions to be
prepared for these changes and encourage commu-
nity engagement in the research process. IRB
approval can include a wider ethical perspective if
relevant clinical trial protocols are required to
describe their community engagement plans, and
these plans are reviewed for their merit as a criterion
in ethical approval.
Engaging in an iterative and collaborative process
with community stakeholders is an investment. Dis-
cussing research priorities and determining best
strategies requires time, effort and ﬁnancial support.
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activities that can improve trial conduct and lay the
foundation for positive collaborations in the future.
In genuinely working together with communities,
while attending to the best participatory practices
possible, researchers, sponsoring institutions and
community stakeholders will see more successful
clinical trial implementation, more effective contro-
versy mitigation and a greater chance of bringing the
ﬁeld closer to discovering new and vital public health
interventions.
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